Sea Young Choo

Seoul National University — South Korea

Medicine · Health Sciences

2h-index24citations14works2.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PARP inhibition in cancer therapy(3), Endoplasmic Reticulum Stress and Disease(2), Cholangiocarcinoma and Gallbladder Cancer Studies(2), interferon and immune responses(2), Cancer-related gene regulation(2)

Publications14 total

Fadraciclib, a CDK2/CDK9 inhibitor, shows efficacy in biliary tract cancer and synergistic potential with olaparib and JQ1 based on MCL1 expression
Cell Communication and Signaling·2025· 1 citedOpen Access
JPI-547, a Dual Inhibitor of PARP/Tankyrase, Shows Antitumor Activity Against Pancreatic Cancers with Homologous Recombination Repair Deficiency or Wnt-Addiction
International Journal of Biological Sciences·2025· 2 citedOpen Access
YAP as a therapeutic target to reverse trastuzumab resistance
Gastric Cancer·2025Open Access
Therapeutic potential of BOLD-100, a GRP78 inhibitor, enhanced by ATR inhibition in pancreatic ductal adenocarcinoma
Cell Communication and Signaling·2025· 4 citedOpen Access
Abstract 1497: PERK as a biomarker to optimize therapy of GRP78 inhibitor, BOLD-100, in gastric cancer
Cancer Research·2025
Abstract 5406: Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker
Cancer Research·2025
Immunomodulatory effects of trastuzumab deruxtecan through the cGAS-STING pathway in gastric cancer cells
Cell Communication and Signaling·2024· 12 citedOpen Access
Abstract 380: Co-downregulation of GRP78 and ATR enhances apoptosis in pancreatic ductal adenocarcinoma
Cancer Research·2024· 1 cited
Abstract 5711: Anti-tumor effects of fadraciclib, CDK2/9 inhibitor, in biliary tract cancer
Cancer Research·2024
Abstract 2599: Trastuzumab deruxtecan reprograms immune response by stimulating cGAS-STING pathway in gastric cancer cells
Cancer Research·2024
The metabolic activity assessed by <sup>18</sup>F-FDG PET and its correlation with tumor immune status and prognosis in advanced biliary tract cancer patients treated with 1L GemCis plus durvalumab +/-tremelimumab.
Journal of Clinical Oncology·2023
Abstract 4496: JPI-547, a dual inhibitor of PARP/Tankyrase, shows promising antitumor activity against pancreatic cancers with homologous recombination repair deficiency or Wnt-addiction
Cancer Research·2023· 1 cited
Abstract 3872: Targeting of YAP overcomes trastuzumab-resistance and promotes immune responses in HER2-positive cancers
Cancer Research·2023· 1 cited
A phase II biomarker-oriented study to evaluate paclitaxel, olaparib, and durvalumab combination in patients with advanced gastric cancer.
Journal of Clinical Oncology·2023· 2 cited

Frequent Co-authors

Kyoung-Seok Oh(14), Ju‐Hee Bang(14), Jeesun Yoon(14), Do‐Youn Oh(14), Ah‐Rong Nam(13), Su In Lee(12), Yoojin Jeong(9), Tae-Yong Kim(8), Jae‐Min Kim(8), Hyo Jung Kim(6), Jae‐Min Kim(6), Tae‐Yong Kim(6), Hyo Jung Kim(5), Yoojin Jeong(5), Dae‐Won Lee(2), Hyo Jung Kim(2), Seock‐Ah Im(1), Banyoon Cheon(1), Hyunju Cha(1), John Kim(1)